Cat. #161773
OV-2295 cell line
Cat. #: 161773
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de Luniversité de Montréal
Primary Citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: OV-2295 cell line
- Alternate name: OV-2295
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer
- Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 6; Pre-treatment
- Morphology: Expresssion of tumor suppressor p53 present. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: semi-compact
- Growth properties: Adherent
- Crispr: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell lines spontaneously derived from solid tumor pre-treatment. Cell line aquired resistance to carboplatin
- Production details: Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement.
- Additional notes: Patient 2295 was diagnosed with ovarian cancer following imaging, ascites puncture, and partial ommentectomy. Patient was included in a clinical trial and treated with cisplatin/topotecan for the first four months following diagnosis. From months 4-7, patient received carboplatin and paclitaxel and responded well to chemotherapy initially. Three months after the end of chemotherapy however, ascites volume increased and later underwent ovarian cytoreduction. Eleven months after diagnosis, she ...
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
- Cultured in antibiotics: Amphotericin B and Gentamicin
References
- Tomas et al. 2023. J Ovarian Res. 11
- 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11
- 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11
- 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4
- 12:856424. PMID: 35600398
